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Abstract
Despite large-scale genome-wide association studies (GWAS), the underlying genes for schizophrenia are largely unknown.
Additional approaches are therefore required to identify the genetic background of this disorder. Here we report findings
from a large gene expression study in peripheral blood of schizophrenia patients and controls. We applied a systems
biology approach to genome-wide expression data from whole blood of 92 medicated and 29 antipsychotic-free
schizophrenia patients and 118 healthy controls. We show that gene expression profiling in whole blood can identify twelve
large gene co-expression modules associated with schizophrenia. Several of these disease related modules are likely to
reflect expression changes due to antipsychotic medication. However, two of the disease modules could be replicated in an
independent second data set involving antipsychotic-free patients and controls. One of these robustly defined disease
modules is significantly enriched with brain-expressed genes and with genetic variants that were implicated in a GWAS
study, which could imply a causal role in schizophrenia etiology. The most highly connected intramodular hub gene in this
module (ABCF1), is located in, and regulated by the major histocompatibility (MHC) complex, which is intriguing in light of
the fact that common allelic variants from the MHC region have been implicated in schizophrenia. This suggests that the
MHC increases schizophrenia susceptibility via altered gene expression of regulatory genes in this network.
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Introduction
Schizophrenia is a severe mental disorder, affecting about 1% of
the population worldwide. Heritability is estimated to be around
80%, but the underlying genes are largely unknown [1]. Large-
scale, genome-wide studies have identified rare genomic micro-
deletions as well as common variants associated with the disease
[2,3,4]. In a recent study, Purcell and colleagues demonstrated
that data from genome-wide association studies (GWAS) for
schizophrenia are compatible with a very large number of loci with
common alleles (N.3,000), each with very small odds ratios
(,1.05) contributing to disease susceptibility [5]. Additional
approaches may be necessary to decipher the genetic basis of
schizophrenia and related disorders [6]. Gene expression is an
intermediate phenotype between gene sequence and complex
traits and can therefore facilitate the study of genetic variation and
disease susceptibility [7]. Genome-wide gene expression profiling
has been used to aid in the discovery of genes involved in human
diseases and to discriminate between disease subtypes [8].
Until now, gene expression studies of schizophrenia have been
limited in size and have primarily made use of post-mortem brain
tissue. Although these studies yielded interesting findings and
highlighted genes involved in several biological pathways
[9,10,11,12,13,14,15] no consistent biological pattern has
emerged. This may be due to the limitation in sample size of
each study as well as confounders that are related to RNA quality
of post-mortem material, such as, post-mortem interval and pH
[13]. For diagnostic purposes, it would be desirable to develop
blood-based biomarkers for schizophrenia since whole blood
collection is non-invasive and can be efficiently performed for
relatively large cohorts of patients and controls even in early stages
of disease manifestation. Although gene expression in whole blood
PLoS ONE | www.plosone.org 1 June 2012 | Volume 7 | Issue 6 | e39498is only moderately correlated with gene expression in brain tissue
[16,17,18,19] several studies suggest that gene expression in blood
could serve as a marker of brain-related disease states, including
schizophrenia [17,18,20,21,22,23,24].
Our study aims to identify genetic mechanisms underlying
schizophrenia using blood-based gene expression profiles. We
obtained genome-wide expression data from 121 schizophrenia
patients (with 92 medicated and 29 antipsychotic-free subjects) and
118 healthy control subjects. Using a co-expression network-based
approach, we identify a schizophrenia-associated cluster of co-
expressed genes that was independent of medication-effects.
Further analysis showed that this cluster is enriched with brain-
expressed genes and that the hub gene is located in and regulated
by the MHC-complex. Our results complement previous GWAS
findings and may highlight new causal candidate genes for
schizophrenia.
Results
Data Preprocessing
Gene expression data were transformed, normalized and
filtered as described in the methods section. Three datasets can
be distinguished and are described in Table 1. Dataset 1 includes
schizophrenia patients on antipsychotics (n=92) and healthy
controls (n=78). Dataset 2 consists of n=29 antipsychotic-free
schizophrenia patients and n=40 healthy controls. This dataset
was used to replicate the results obtained with dataset 1.
Network Reconstruction in Schizophrenia Cases and
Controls
Network reconstruction. A weighted gene co-expression
network was constructed using dataset 1, independent of disease
status, as described in the Methods section. For this, the 5,000
most variable transcripts were selected. The variance of the
expression of these genes ranges from HLA-A29.1 (average
expression =12.10, variance =5.60) to MSLN (average expres-
sion =7.46, variance =0.04). Application of WGCNA pro-
cedure to genome-wide data (16,707 genes) results in almost
identical findings (Table S1). The selection of the 5,000 most
variable transcripts was used in a hierarchical clustering pro-
cedure to identify groups of co-expressed genes, termed
‘modules’. These correspond to the branches of the resulting
clustering tree. Each module is assigned a unique color label,
which is visualized in the color band underneath the cluster tree
(Figure 1). We identified 14 modules ranging in size from 115
genes in the Cyan module to 789 in the Turquoise module. We
also defined an improper (grey) module with genes not belonging
to any of the 14 proper modules. The expression profiles of
transcripts inside a given module were summarized by their first
principal component (referred to as module eigengene). The
module eigengene is a weighted (quantitative) average of the
module gene expression profiles.
Co-expression modules related to schizophrenia
status. To identify modules related to schizophrenia disease
status, we regressed each of the 14 module eigengenes on disease
status. Strikingly, 12 out of the 14 modules were significantly
(FDR corrected p,0.05) associated with schizophrenia status in
dataset 1 (Table 2). Of these 12 associated modules, the Green,
Tan, Red, Yellow, Black and Pink modules were negatively
correlated with schizophrenia, meaning that the genes in these
modules are predominantly under-expressed in schizophrenia
cases. In contrast, the Magenta, Turquoise, Salmon, Blue, Cyan
and Greenyellow modules were positively correlated with disease
status, containing mostly genes over-expressed in schizophrenia.
Replication of Co-expression Network Results in the
Antipsychotic-free Dataset
Network preservation in the antipsychotic-free
dataset. Based on our data, we hypothesized that the large-
scale differential gene expression observed in schizophrenia
patients might be caused by antipsychotic drug treatment. To
test this hypothesis and to eliminate possible confounding effect of
antipsychotic medication on gene expression profiles, a second
dataset of antipsychotic-free schizophrenia patients (n=29) and
unaffected controls (n=40) was used to replicate the results (see
Table 1). Of the 5,000 genes used to construct the previous
network, 4,464 (89%) were also present in dataset 2, representing
the overlap between the Illumina H-8 and H-12 arrays. WGCNA
was performed for this dataset separately, using the module
assignment (color codes) of the previous dataset. To quantitatively
assess whether a specific module is preserved, we used a module
preservation Z statistic implemented in the modulePreservation
function of the WGCNA R library [25,26]. A Z-statistic value
larger than 2 indicates that the corresponding module is
significantly preserved in the second set. We find that all of our
modules have a preservation Z score larger than 8, which shows
Table 1. Description of datasets.
1: Schizophrenia dataset 2: Antipsychotic-free dataset
Controls Cases Controls Cases
Total 78 92 40 29
Mean age 41 yrs 41 yrs 30 yrs 31 yrs
Gender 31M, 47F 66M, 26F 27M, 13F 21M, 8F
Batch 1 22 15
Batch 2 78 92 18 14
Country* 22 DK, 56 NL 92 NL 6 DK, 34 NL 6 DK, 23 NL
Expression Array Illumina H-12 (16,707 genes) Illumina H-8 & H-12 (12,704 genes)
For this study, three datasets were used; schizophrenia cases and controls, an antipsychotic-free set and a control dataset. Age and gender information is given for cases
and controls separately. Gene expression data was generated in two batches (batch 1: Illumina H-8 and batch 2: Illumina H-12) and collected at different sites,
information given in the fourth and fifth row). The batch effect resulting from the use of different arrays on different time points in the latter set was removed using the
SampleNetwork R package [62]. The number of expressed genes is given in the last row. *DK = Denmark and NL = The Netherlands.
doi:10.1371/journal.pone.0039498.t001
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schizophrenia cases/controls and the antipsychotic-free dataset
(Figure S1).
Gene co-expression modules related to schizophrenia
status in antipsychotic-free set. The module eigengenes of
the twelve modules that showed significant disease associations in
the discovery dataset were examined in the antipsychotic-free data
set using a regression analysis with a FDR of 5%. For only two
(Tan and Salmon) out of 12 schizophrenia related modules could
the disease association be replicated (p,0.05) in the second,
antipsychotic-free, dataset. The Greenyellow module is also
significantly associated with disease status in dataset 2 but in the
opposite direction, i.e. its disease association cannot be replicated.
Results are summarized in Table 2.
Enrichment for Blood Cell Type Markers and Brain-
expressed Genes
Module content reflects blood cell types. A previous study
identified genes of which expression was correlated to major
Figure 1. Network construction identifies distinct modules of co-expressed genes. The network was constructed using gene expression
data of 92 medicated schizophrenia cases and 78 controls (dataset 1). The dendrogram was produced by average linkage hierarchical clustering of
genes using 1-topological overlap as dissimilarity measure (see methods section). Modules of co-expressed genes were assigned colors
corresponding to the branches indicated by the horizontal bar beneath the dendrogram.
doi:10.1371/journal.pone.0039498.g001
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lymphocyte count (56 genes) and red blood cell size (56 genes))
[27]. These lists of genes were taken as input for the
userListEnrichment function incorporated in the WGCNA
package [28] that compares the number of overlapping genes
to the maximal possible overlap. We find both the Black (11/35
of genes overlap; 31%, p=5.6610
24) and the Brown (9/35 genes
overlap; 26% p=6.9610
24) module to be enriched for markers
of the most prevalent leukocytes: neutrophils. The Red module
was enriched for lymphocyte markers (10/37 genes overlap;
27%, p=2.3610
25) and the Yellow module for red blood cell
size markers (22/29 genes overlap; 76%, p=9.3610
221). Finally,
Whitney and colleagues [27] defined a set of 30 genes correlated
with time of blood draw, that were overrepresented in our Cyan
module (5/15 genes overlap; 33%, p=5.5610
27). No significant
enrichment with blood cell markers could be found for the two
validated disease modules (Tan and Salmon).
Enrichment of brain-expressed genes in disease-
associated module. Next, we examined whether the two
validated schizophrenia modules (Tan and Salmon) were enriched
for brain-expressed genes using a publically available brain
expression dataset [29]. Table 2 shows that the Tan module
contains the highest number of genes expressed in brain (61%),
followed by the Salmon module (52%). In comparison, 45% of the
genes in the 10 non-significant modules were expressed in brain.
When formally tested, the Tan module was the only module that
was significantly enriched with brain-expressed genes (Fisher
p=4.3610
24). Using the userListEnrichment function, we did not
find the Tan module as a whole, or the subset of brain-expressed
genes, to be enriched for markers of particular neuronal cell types
(astrocytes, oligodendrocytes or neurons) [28,30].
Inner Module Structure and Genetic Control of the Tan
Schizophrenia Module
To determine genes that are centrally located in the Tan
module, we calculated the intramodular connectivity. The
intramodular connectivity (k-within) was calculated for each gene
by summing the connection strengths with other module genes
and dividing this number by the maximum intramodular
connectivity. Genes with high intramodular connectivity are
informally referred to as intramodular hub genes. The k-within
statistics for the genes in the Tan module are presented in Table
S2. In the Tan module, ABCF1 (ATP-binding cassette, sub-family
F( GCN20), member 1) on chromosome 6p is the most connected
gene. We consulted a publically available human expression
quantitative trait loci (eQTL) database generated on lymphoblas-
toid cells [31]. In the Tan module we find SLC2A6, SDHA,
DHRS1, sep-06, CNDP2, SIGIRR, FBXL5, DHX58 and the hub
gene ABCF1 to be in the list of heritable cis-regulated genes (LOD
score and heritability estimates for genes in the Tan module from
Dixon and colleagues [31] are given in Table S2). A visual
representation of the Tan inner module structure and content is
given in Figure 2.
Gene Ontology Analysis of the Tan Schizophrenia
Module
Ontology was assessed using Ingenuity (IngenuityH Systems,
www.ingenuity.com). Categories were considered significantly
enriched when p,0.001. Top enriched categories for the Tan
module include Cellular Development (smallest p-val-
ue=4.2610
25),HematologicalSystemDevelopmentandFunction
(smallestp=4.2610
25),Hematopoiesis(smallestp=4.2610
25)and
Gene Expression (smallest p=5.6610
25). Also, among others, the
functional category Neurological Disease (smallest p=2.6610
24)
was significantly enriched, containing the genes CCL5, PRKCQ,
PTAFR, AKR1B1, CD247, IL10RA and KHSRP. A complete
Table 2. Module eigengene significance for co-expression modules.
Schizophrenia dataset Antipsychotic-free dataset
WGCNA Modules # genes t Adjusted p-value t Adjusted p-value Expressed in brain
Green 367 26.26 3.8610
210 20.99 4.8610
201 -
Magenta 226 5.51 3.5610
208 20.24 9.6610
201 -
Tan 129 24.92 8.8610
207 22.61 4.8610
202 61%
Red 344 24.63 3.6610
206 21.60 2.2610
201 -
Turquoise 789 4.37 1.3 x10
205 1.97 1.2610
201 -
Yellow 399 23.82 1.3610
204 21.26 3.6610
201 -
Salmon 121 3.02 2.5610
203 2.51 4.8610
202 52%
Blue 610 2.95 3.2610
203 2.04 1.2610
201 -
Cyan 115 2.87 4.1610
203 20.13 9.6610
201 -
Greenyellow 197 2.59 9.7610
203 22.51 4.8610
202 -
Black 321 22.09 3.6610
202 0.33 9.6610
201 -
Pink 290 22.03 4.2610
202 20.05 9.6610
201 -
Purple 205 21.07 2.9610
201 -- -
Brown 447 20.24 8.1610
201 -- -
The modules that were found by WGCNA in the first dataset are listed together with the number of genes they contain (shown in the second column). Differences in
cases and controls were tested using a linear model with FDR correction. Results for the medicated cases versus controls are presented in column three and four. The
modules that were found to be differentially expressed were also tested for significance between cases and controls in the antipsychotic-free set, and results are
presented in the fifth and sixth column. The last column indicates the percentage of module content that was also found to be expressed in brain (log2.4). For all
genes in the other modules, this was found to be 45%. For the Tan module, this was significantly higher (Fisher p=4.3610
24).
doi:10.1371/journal.pone.0039498.t002
Genes and Pathways Underlying Schizophrenia
PLoS ONE | www.plosone.org 4 June 2012 | Volume 7 | Issue 6 | e39498overview of the Ingenuity results for the Tan module is given in
Table S3. As a caveat, we mention that results from pathway
analyses need to be interpreted with some caution since enrichment
results can be biased towards well-defined pathways and larger
pathways [32]. Therefore, the Ingenuity analysis in this study is
primarilyusedasanexplorativetoolforexaminingthegenecontent
of the modules of interest.
Genome Wide Association Results for Genes in the Tan
Schizophrenia Module
We also evaluated the enrichment of the modules with respect
to disease related SNPs from a previously published schizophrenia
genome wise association study. (1,378 controls and 1,351 cases,
NCBI dbGaP analysis accession: pha002857.v1.p1). 115 of the
129 genes in the Tan module were represented by 1,714 SNPs.
Visual inspection of the Quantile-Quantile plots (Supporting
Information S1) suggests enrichment of the Tan module for
nominally associated (p,0.05) SNPs. We used Fishers Exact to test
for enrichment of nominally associated SNPs against an expected
proportion of 5%. We found a significant enrichment of SNPs with
p,0.05 (Fishers Exact p=1.5610
25, 151 out of 1714 SNPs).
Because one gene is represented by multiple SNPs and multiple
significant SNPs in one gene could bias the test, we next took the
lowest p-value per gene (Table S1). Enrichment was significant
(Fishers Exact p=2.7610
27, 36 out of 115 SNPs with p,0.05).
Validation of Differential Gene Expression
Real-time quantitative PCR (qPCR) experiments were per-
formed in order to validate expression changes of the number one
hub gene of the Tan schizophrenia module, ABCF1 as well as the
gene with the highest log fold change in this module, GZMH.W e
used 165 of the same samples as were used for array hybridization
for qPCR validation; for a subset of subjects (n=34) there was no
RNA left but we had access to a second blood draw from which
RNA had been extracted. We applied stringent quality control
procedures as described in the methods section. For ABCF1,w e
were able to test differential expression in 97 cases and 83 controls
whereas measurements for GZMH were more variable, leaving 79
cases and 83 controls for analysis. Since high qPCR DCt values
represent low expression, we expect an inverse correlation with
Illumina expression values. Indeed, residuals of Illumina expres-
sion values and qPCR DCt values are highly negatively correlated
(Spearman’s rank correlation ABCF1, r=-0.60, p,2.2e-16;
GZMH, r=20.88, p,2.2e-16). When only selecting the original
Figure 2. Visual representation of connections of genes in the Tan schizophrenia module. This figure shows target genes of the probes in
the Tan schizophrenia module with the strongest connections only (r .0.64). Blue-colored nodes represent brain-expressed genes. Square-shape
nodes indicate cis-regulation. Node size is related to the number of connections of that particular gene; a highly connected gene (i.e. ‘hub gene’) is
therefore larger than genes with fewer connections. Red text indicates genes previously implicated in schizophrenia. Image created using Cytoscape
software [69].
doi:10.1371/journal.pone.0039498.g002
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lation ABCF1, r=20.69, p,2.2e-16; GZMH, r=20.90, p,2.2e-
16). Confirming Illumina results; ABCF1 showed decreased
expression in cases versus controls (Wilcoxon Ranks sum test,
W=2636, p=6.7610
25, fold change (2
-DDCt) =0.86). GZMH
reached nominal significance (Wilcoxon Ranks sum test,
W=2353, p=3.8610
22, fold change (2
-DDCt) =0.84). confirming
decreased expression in cases.
Discussion
In this study we utilize gene expression data to identify genes
involved in schizophrenia. We identified 2 co-expression modules
(gene networks) that consistently relate to schizophrenia status in
two independent data sets. One of these modules (under-expressed
in schizophrenia patients) was significantly enriched with brain-
expressed genes, leading us to focus on this module. The most
central (‘hub’) gene in this network, ABCF1,i scis-regulated, which
means that nearby genetic variation indirectly/directly regulates
this schizophrenia-associated gene expression network. Using data
from a previously published GWAS [33] the overall genes
represented in this network are enriched with SNPs nominally
associated with schizophrenia, providing further support that this
network has a primary role in schizophrenia susceptibility.
In the first test data set, we identified 12 gene co-expression
networks (further called modules) that were associated with
schizophrenia disease status, reflecting the large number of
individual genes found in the differential expression analysis. By
relating modules and intramodular hub genes to disease status and
SNPs, our systems genetic approach (WGCNA) alleviates the
multiple comparison problem inherent in the data: only 14
modules were tested for association instead of .23,000 genes
[25,34,35,36].
To address the concern of expression changes induced by the
effects of antipsychotics, we evaluated our modules in a second
validation dataset of antipsychotic-free samples and found all 14
modules to be highly preserved between datasets, confirming
previous observations that it is possible to infer stable and
reproducible modules using whole blood RNA expression profiles
[37,38]. In addition, real-time qPCR experiments validated
expression changes in the number one hub gene in the Tan
schizophrenia module, ABCF1, as well as the gene with the highest
log fold change, GZMH. Although all modules were found to be
preserved, only 2 of the 12 schizophrenia-related modules
remained significantly related to disease status in the validation
data set of antipsychotic-free samples: the Salmon and Tan
module. The fact that 10 of the 12 modules were not associated
with schizophrenia in the replication set may reflect large-scale
effects of antipsychotic medication on gene expression in blood.
This phenomenon warrants further investigation since the
majority of schizophrenia patients is readily treated and thus
may bias other studies likewise. Since schizophrenia is a severe
mental disorder often presenting with acute psychosis, it is a major
challenge to recruit patients that have not yet received antipsy-
chotic medication. Other considerations that may affect the
replication may be the relative small sample size of the 40 controls
and 29 antipsychotic-free cases that was used in the second stage,
and the source of sampling with no medicated patients collected in
Denmark. Due to limited availability of clinical data on the
subjects it was not possible to investigate differences in symptom
profile, or other parameters such as age of onset. However, there is
no evidence that this has led to a systematic bias or a less
representative patient group. Nevertheless, the strong conservation
of the modules of co-expressed genes in the replication sample and
the consistent finding of two modules associated with schizophre-
nia provide a strong lead for further study.
As expected we find that many co-expression modules reflect
blood cell types. Two modules (Blue and Brown) were enriched for
neutrophil markers, the most common leukocyte. The Red
module was enriched for lymphocyte markers and the Yellow
module for red blood cell size markers. Finally, the Cyan module
was enriched for genes related to time of blood draw. We did not
find that the disease-associated modules (Tan and Salmon) relate
to the studied blood cell markers. Since schizophrenia is a brain-
related disorder, the question remains whether whole blood gene
expression profiles can be informative for analysis. We therefore
tested the two significant modules for enrichment of brain-
expressed genes, with the assumption that if a module is enriched,
this should prioritize our efforts. Interestingly, out of all of the
observed modules, only the Tan module is significantly enriched
for brain-expressed genes. For this reason we consider the Tan
module the most likely to contain genes underlying neuropsychi-
atric disease. Since we do not have blood and brain samples
available from the same individuals, we cannot formally correlate
the expression values in these two tissue types.
The gene content and connections for the Tan schizophrenia
module are visually represented in Figure 2. Besides categories
related to hematological function, the Tan schizophrenia module
was also enriched for the Neurological Disease category (CCL5,
PRKCQ, PTAFR, AKR1B1, CD247, IL10RA and KHSRP).
Moreover, this module was found to contain two genes
previously suggested to be involved in schizophrenia; namely
Catechol-O-methyltransferase (COMT) and phosphatidyl-inositol-
4-kinase-catalytic-a (PIK4CA). COMT is involved in the de-
generation of endogenous catecholamines as well as in the
metabolism of drugs used in many neuropsychiatric diseases.
Results from association studies of the common Val158/108Met
polymorphism with schizophrenia, however, remain ambiguous
[39,40,41,42]. The PIK4CA gene is a catalytic enzyme in the
phosphatidylinositol (PI) pathway, involved in the regulation of
signal transduction, synaptic transmission and possibly of cell
shape of neurons or oligodendrocytes. Like COMT, this gene has
been linked to psychiatric traits associated with the 22 q11.2
deletion syndrome [43,44], which is in turn characterized by
increased prevalence of psychotic symptoms [45,46].
Previous studies of blood based gene expression of schizophre-
nia have been modest in size and identified a number of
differentially expressed genes but without a consistent pattern
[21,47,48]. Our relatively large sample size allows us to evaluate
previous findings. One study found 123 genes to be differentially
expressed in blood, of which 6 showed the same pattern in brain
[23]. Our results do not confirm differential expression of these 6
genes. A later study attempting to validate the differential
expression of 7 genes from previous studies was only able to
confirm the differential expression of CXCL1 [49]. Our study did
not confirm differential expression of CXCL1, but of the other 6
genes, S100A9 (under-expressed in schizophrenia) was found in the
Yellow module, one of the modules that is negatively associated to
schizophrenia in the medicated dataset.
A larger sample of 49 Japanese antipsychotic-free patients and
52 controls resulted in 792 differentially expressed probes in whole
blood. A supervised artificial neural network analysis identified 14
of these as a predictor set for diagnosis with an accuracy of 91.2%
[50]. Of the 8 known genes in this list, PGRMC1 was located in the
Blue module, confirming over-expression in schizophrenia. The
largest Caucasian blood-based study of schizophrenia consists of
32 untreated patients and 32 matched controls found 180
differentially expressed genes [24]. Of the under expressed genes
Genes and Pathways Underlying Schizophrenia
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medicated dataset. Of the over expressed genes (79 known genes),
10 are located in modules positively related to disease status in the
medicated dataset. Gene expression analysis in whole blood has
been used to investigate the association of psychosis with the
ubiquitin proteasome system [51,52] and a top list of 31 genes
[53]. We could only confirm down-regulation of TCF4 (located in
the Red module). The limited overlap in findings characterized
gene expression studies of schizophrenia so far both in blood and
brain. Although our study confirms a subset of genes found in
previous studies, none of them are located in the Tan schizophre-
nia module. This may result from our large sample size and the
fact that we had access to an independent antipsychotic-free
sample set to validate our results. Of the genes in the Tan
schizophrenia module, 18 genes (YARS, AARS, MAGED1,
HSP90AB1, AKR1B1, NUP93, SNX17, DDOST, PSMB2, NCALD,
ACOT7, IMP3, SARS, GLG1, COMT, MXD4, GPR177, ARAF) do
overlap with co-expression modules constructed using brain tissue
and associated with schizophrenia previously [15]. In addition,
three genes (ALDOC, ENO1, SDHA) were found to be differentially
expressed in previous microarray studies examining brain (over-
view in [15]).
Intramodular hub genes in disease related modules have been
found to be biologically and clinically interesting genes in several
disease applications [54,55]. The most connected intramodular
hub gene in the Tan module is ABCF1 (ATP-binding cassette, sub-
family F (GCN20), member 1). This gene is located within the
MHC region at chromosome 6p. This gene-dense region is
essential to the immune system and contains many human
polymorphisms [56]. Common variants from the MHC region
have been reported to be associated with schizophrenia [2,3].
The fact that the expression of hub gene ABCF1 was found to be
cis-regulated in a previous study suggests that a key member from
the Tan module is regulated by the MHC region and in turn
drives other genes in the module [31,57]. The Tan module also
contains a number of other genes within the MHC region: heat
shock protein 90 kDa alpha (cytosolic), class B member 1
(HSP90AB1); ring finger protein 1 (RING1); casein kinase 2, beta
polypeptide (CSNK2B) and tubulin, beta (TUBB).
Our results coincide with the findings of existing GWAS studies
for schizophrenia that highlighted involvement of the MHC region
in disease susceptibility [2,3]. While GWAS studies included
thousands of subjects, our study in contrast involved a few
hundred cases and controls. Moreover, gene expression data
highlights individual genes within the MHC region that are
differentially expressed in schizophrenia while the association
signal observed in the GWAS studies are dealing with extensive
patterns of linkage disequilibrium without the ability of pinpoint-
ing single candidate genes.
It is striking that the robustly defined (Tan) schizophrenia
module was significantly enriched with nominally significant SNPs
from a GWAS study. This corroborates the fact that this module is
independent of drug effects and represents primary disease effects.
Previous studies find enrichment of disease related SNPs in their
co-expression modules of interest, implicating that these modules
represent causal effects [58,59]. In addition, this approach
highlights the fact that network analyses can be used to reconstruct
molecular phenotypes for the identification of the genetic
association signal derived from pathways, rather than small effects
from individual genes.
Overall we show that gene expression profiling in whole blood
provides new insight in the molecular networks that may underlie
schizophrenia. By making use of an antipsychotic-free patient
sample, we were able to replicate our findings and filter out large-
scale medication effects. The Tan schizophrenia module that we
identified is enriched with brain-expressed genes In addition; there
is enrichment of association signal in GWAS, which further
supports causal involvement in disease susceptibility. Moreover the
association of genetic variants in the MHC region with the hub
genes of this Tan schizophrenia module suggests that recent MHC
association findings may increase schizophrenia susceptibility via
altered gene expression of regulatory genes in this network. Future
studies involving suitable model systems could aim to validate
these causal hypotheses.
Materials and Methods
Subjects
Participants were recruited from three sources: i) the De-
partment of Psychiatry of the University Medical Center Utrecht
(90 controls and 113 cases), ii) Parnassia PsychoMedical Center in
the The Netherlands (2 cases) and iii) the Center for Neuropsy-
chiatric Schizophrenia Research, Psychiatric Center Glostrup,
Denmark (28 controls and 6 cases). Diagnoses were determined by
Standardized Psychiatric interviews either The Comprehensive
Assessment of Symptoms and History (CASH) or the Composite
international diagnostic interview (CIDI) by trained clinicians.
Schizophrenia was defined by a DSM-IV-TR diagnosis of
#295.0–295.89, and #298.9. All participants gave written
informed consent. This study was approved by Medical Research
Ethics Committee (METC) of the University Medical Center
Utrecht, The Netherlands (accredited on November 1
st’, 1999 by
ex section16 of the WMO) (collection in both Utrecht and the
Hague) and the Committees on Biomedical Research Ethics for
the Capital Region of Denmark. Antipsychotic-free patients were
not on antipsychotics during the six-month-period prior to blood
sampling. Only cases with a DSM IV #295.0–295.89 and #298.9
diagnoses were included to increase clinical homogeneity. Since
ethnic heterogeneity and relatedness may affect the distribution of
genetic variation and consequently gene expression, we removed
non-Caucasian subjects as well as closely related subjects as
described below. Questionnaire data on ethnicity and relatedness
was available for all subjects. In addition, for 119 of the samples in
dataset 1 and 2, SNP data was available on Illumina CytoSNP
330k and ethnicity could be assessed using clustering procedures
and multidimensional scaling in Plink [60]. After exclusion based
on quality control (6 subjects), ethnicity (15 subjects, .2SD from
the mean of first two principal components), diagnosis (7 subjects)
and relatedness (2 subjects, piHat =0.1), 29 antipsychotic free
patients, 92 medicated patients and 118 controls remained.
Demographic information for both datasets is given in Table 1.
Expression Arrays
For isolation and purification of mRNA from whole blood the
PAXgene extraction kit (Qiagen) were used for all samples.
PAXgene tubes were stored in 220uC and RNA was isolated
within 6 months after phlebotomy according to the manufacturer’s
instructions including an optional DNase digestion step. Total
mRNA was quantified using a ribogreen assay (Invitrogen Quant-
it
TM Ribogreen). Quality of total RNA was determined using
Agilent 2100 Bioanalyzer. A threshold of RNA integrity number
(RIN) of 7 was taken for selection of RNA samples. Data was
generated in two batches. Genome-wide RNA expression profiling
was obtained with the Illumina HumanRef-8 V3 arrays for batch
1 and HumanRef-12 V3 arrays for batch 2 using Illumina’s
standard protocol at UCLA Illumina facility. The raw microarray
data is MIAME compliant and made available at gene expression
omnibus (GEO) under accession GSE38485.
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BeadStudio software version 3.2.3 was used to extract raw
data and generate background-corrected gene expression data.
Further pre-processing was done using the Lumi package for R. A
variance stabilizing transformation (VST) and robust spline
normalization (RSN) were applied to the data according to the
Lumi procedure [61]. Genes were then filtered based on detection
values generated by BeadStudio. Expression probes had to reach
the detection p-value threshold ,0.01 in at least one sample. Data
was split into two datasets, one containing 92 schizophrenia cases
and 78 controls, the second all antipsychotic-free subjects (n=29)
and controls (n=40). Batch effects resulting from the use of
different arrays at different time points were removed using the
SampleNetwork R function [62]. Data on the probe level was
collapsed to genes for separate datasets prior to analyses. When
two probes were available (this is the case for most genes) the
probe with the highest maximum expression level was selected. In
case of three or more probes per gene, the probe with the highest
maximum connectivity was selected. This resulted in 16,707 genes
in dataset 1 and 12,704 genes in dataset 2.
Weighted Gene Co-expression Network Analysis
(WGCNA)
To identify co-expression modules, we used WGCNA
[25,36,63,64,65]. A detailed description can be found in Support-
ing Information S2. In short, a weighted adjacency matrix
containing pair-wise connection strengths was constructed by
using the soft-thresholding approach (b=6) on the matrix of pair-
wise correlation coefficients. A connectivity measure (k) per gene
was calculated by summing the connection strengths with other
genes. Modules were defined as branches of a hierarchical
clustering tree using a dissimilarity measure (1 - topological
overlap matrix [36,66]). Each module is subsequently assigned
a color. Preservation of module structure was assessed using the
modulePreservation R function [26]. The gene expression profiles
of each module were summarized by the module eigengene
(defined as the first principal component of the module expression
levels). Each module eigengene was regressed on disease status
(with age and gender as covariates) using the linear model in the
limma R package (FDR 5%) [67].
Public Brain Expression Data
The brain expression data was retrieved via GEO (GSE8919),
and consists of 193 neuropathologically normal human brain
samples (frontal and temporal cortex) on Illumina HumanRef6
Expression BeadChips [29]. After quality control (using the
SampleNetwork R package [62]) 156 samples were used including
24,354 probes collapsed to 19,880 genes. Of these genes, 7,999
(48%) overlap with the 16,707 well-detected genes on the H-12
array. Expression probes had to reach the threshold of a mean log2
expression value .4 across all samples to indicate expression in
brain (met by 5,753 of the 7,999 (72%) overlapping genes).
Significance of overrepresentation (Bonferroni corrected p,0.05)
was assessed using Fisher’s exact test for count data (hypergeo-
metric distribution).
Testing Significance of Module in GWAS
Data from a previous schizophrenia GWAS study (NCBI
dbGaP analysis accession: pha002857.v1.p1) was available for
1378 controls and 1351 cases, with 729,454 SNPs genotyped using
the Affymetrix 6.0 array. We generated a list of SNPs within
a 10 kb region around the genes in the co-expression modules and
subsequently extracted the empirical p-values from the GWAS
results. Significance of overrepresentation was assessed using
Fisher’s exact test for count data (hypergeometric distribution).
Real-time Quantitative PCR (qPCR) Experiments
Sufficient RNA from the original sample was available for 80
cases (65 medicated and 15 antipsychotic-free patients) and 85
controls. For another 8 controls and 26 cases the original sample
was depleted, but RNA from a second blood tube was available.
Total RNA, isolated as previously described, was reverse
transcribed to cDNA using the High-Capacity RNA-to-cDNA
Kit (AppliedBiosystems) according to manufacturer’s protocol.
Following standard protocols, real-time PCR was executed using
TaqMan gene expression assays (AppliedBiosystems) for GZMH
(Hs00277212_m1), ABCF1 (Hs00153703_m1) and GAPDH
(Hs03929097_g1) and analyzed on an ABI Prism 7900 System.
For all genes, absolute quantities were obtained by running all
samples in triplicates. Samples were excluded when raw Ct.35 or
SD.0.5 per triplicate. In addition, measurements were excluded
when average triplicate Ct values were outside 62SD per plate for
each gene. Ct values were normalized against GAPDH expression
(DCt). Samples were excluded when DCt outside 62SD. Since
Illumina expression values were initially subidivided into two
datasets, residuals were calculated for a model including dataset as
well as age and gender. Residuals for DCt values were calculated
for a model including pcr plate, age and gender. All residuals were
generated using the regression function in the Limma package for
R [67]. Differential expression between schizophrenia cases and
healthy controls was tested by the Wilcoxon Ranks sum test using
the MASS package for R [68].
Supporting Information
Figure S1 Preservation of modules between datasets. A
co-expression network for dataset 2 (29 antipsychotic-free and 40
controls) was constructed, using module assignments of dataset 1.
The preservation Z-statistic is larger than 2 for all modules,
indicating significant module preservation between datasets.
(DOC)
Table S1 Results of genome-wide WGCNA. This table
contains counts per module for WGCNA performed on genome-
wide data (16,707) as compared to analysis performed on the
5,000 most variable genes. The first two columns indicate the
modules generated on genome-wide data and the number of genes
they contain (highlighted in blue). Horizontally, the first two rows
contain the results from the 5,000 most variable genes and their
gene counts (highlighted in blue). Color assignments depends on
the size of the modules, therefore this is not the same. However,
the number of overlapping genes indicates similar grouping in
modules. Most of the genes not included in the 5,000 most varying
genes are located in the grey ‘noise’ module. The lightgreen
module with ABCF1 as a hub gene contains most genes from the
original Tan module. The directionality of the association with
schizophrenia disease status remains the same, as is the case for the
other modules (module trait correlations and p-values are given).
(XLS)
Table S2 Module content of Tan module. Table contains
genes in Tan module. Gene symbol, chromosome, k-within
statistics, brain-expressed status and log fold changes are given.
Expression data is transformed (variance stabilizing method) and
normalized (robust spline) yielding values comparable to log2
values. Finally, LOD scores and heritability of cis-regulated genes
identified in a previous study [31] are given.
(XLS)
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pathway results for genes in the Tan module.
(XLS)
Supporting Information S1 Q-Q plots for Tan module.
For 115 out of the 129 genes in the Tan module, data from
a previous schizophrenia GWAS study was available. Q-Q plots
are given for the SNPs in
(DOC)
Supporting Information S2 Weighted gene co-expression
network analysis. A detailed description of the WGCNA
method used in this study.
(DOC)
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